UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (date of earliest event reported): October 16, 2009
Apollo
Medical Holdings, Inc.
(Exact
Name of Registrant as Specified in its Charter)
|
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
000-25809
(Commission
File Number)
|
20-8046599
(I.R.S.
Employer
Identification
No.)
|
|
|
1010
N Central Avenue
Glendale,
California 91202
(Address
of Principal Executive Offices)
(818)
507-4617
(Registrant’s
Telephone Number)
|
|
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
Explanatory
Note
This
amended Current Report on Form 8-K/A (the “8-K/A”) is being filed in order to
correct a misstatement in registrant’s Current Report on Form 8-K filed on
October 19, 2009 (the “Original 8-K”)
relating to the number of warrants issued to Syndicated Capital, Inc., a FINRA
member firm that acted as placement agent (the “Placement Agent”) in
connection with the private placement transaction reported in the Original 8-K
(the “Private
Placement”).
The
Original 8-K incorrectly disclosed that in connection with the Private Placement
the Placement Agent received five-year warrants to purchase up to 150,000 shares
of the Common Stock at an initial exercise price per share of
$0.25. However, the Placement Agent actually received five-year
warrants to purchase up to 250,000 shares of the Common Stock at an initial
exercise price of $0.25 per share of Common Stock.
Except
for the correction herein as to the number of warrants issued to the Placement
Agent in the Private Placement, this 8-K/A does not amend or update any other
information contained in the Original 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
APOLLO
MEDICAL HOLDINGS, INC.
|
|
| |
|
|
|
|
|
By:
|
/s/
A. NOEL DEWINTER |
|
| |
|
A.
Noel DeWinter |
|
| |
|
Chief
Financial Officer |
|
| |
|
|
|